Core Insights - The company ended 2025 with strong execution, achieving revenue growth in both interventional glaucoma and interventional dry eye segments, and aims for double-digit growth in 2026 while maintaining operational discipline [1][16] - The interventional technologies, OMNI and TearCare, target prevalent diseases such as glaucoma and dry eye, presenting significant long-term market opportunities [1][5] Financial Performance - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year, with interventional glaucoma revenue at $19.7 million (up 5%) and interventional dry eye revenue at $700,000 (up from $300,000) [17][18] - Gross margins were strong, with interventional glaucoma at 88% and interventional dry eye improving to 68% [18] - Operating expenses decreased by 25% to $21.5 million, reflecting cost management efforts, including a reduction in force [18][19] Market Strategy - The company is focusing on interventional glaucoma and interventional dry eye, with a strategy to enhance customer engagement and expand market access [6][12] - The interventional dry eye segment is expected to grow significantly, with a revenue guidance of $5 million to $7 million for 2026, compared to $1.6 million in the prior year [20] - The company aims to pioneer the reimbursed interventional dry eye market, having established pricing for the TearCare procedure with two MACs [8][12] Growth Drivers - The interventional glaucoma market is expected to grow in the low- to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [20][26] - The company is investing in commercial infrastructure to support growth in both interventional segments, particularly in areas with established reimbursement [12][41] - The potential for TearCare is significant, with an estimated 700,000 patients in the targeted MAC regions suffering from moderate to severe dry eye disease [44][50] Future Outlook - Revenue guidance for 2026 is set at $82 million to $88 million, reflecting a growth of 6% to 14% compared to 2025 [20][22] - The company anticipates that the first quarter of 2026 will be the lowest for interventional glaucoma, with expectations for growth in the second half of the year [21][56] - Continued engagement with additional MACs and commercial payers is critical for expanding access and accelerating adoption of interventional dry eye treatments [12][61]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17][19] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts and higher average selling prices [14] - The company is focused on expanding the interventional dry eye market through investments in commercial infrastructure and provider engagement [11][12] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye segment is projected to reach $5 million-$7 million in revenue for 2026 [20][26] - The company estimates that the current MIGS market is approximately 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [37] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye categories [7] - The company is investing in targeted commercial resources to drive education and activation in the standalone glaucoma market [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, supported by a strong balance sheet [17] - The company is optimistic about the growth potential in both interventional glaucoma and interventional dry eye markets, with a focus on disciplined execution [22] - Management highlighted the importance of expanding market access and engaging with additional MACs and commercial payers throughout 2026 [12][22] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company ended Q4 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and expressed excitement about growth in both segments for 2026 [25][26] Question: Underlying market growth assumptions for interventional glaucoma - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: Standalone glaucoma market evolution and obstacles - Management discussed the need for education and activation to convert understanding of interventions into actual cases, with a focus on procedural workflows [34][36] Question: Operating expenses and investment balance - Management emphasized a focus on commercial infrastructure investments while maintaining financial discipline [44][46] Question: Revenue opportunity in MACs for dry eye - Management highlighted a significant market opportunity in MACs with 10.4 million covered lives and a high prevalence of dry eye disease [47][49] Question: Peak sales potential for TearCare - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [55][56] Question: Impact of new goniotomy codes on reimbursement - Management discussed potential changes in reimbursement for goniotomy and its implications for OMNI technology [69][70]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, driven by increases in ordering accounts and average selling prices [17] - Interventional dry eye revenue was $0.7 million, up from $0.3 million, reflecting positive traction in the reimbursed interventional dry eye business model [17] - Gross margin was 87%, consistent with the prior year, while interventional glaucoma gross margin improved to 88% from 87% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] Business Line Data and Key Metrics Changes - Interventional dry eye segment achieved a significant reimbursement milestone with established pricing for CPT code 0563T, associated with the TearCare procedure [9] - Revenue from interventional dry eye in Q4 was driven by the sale of approximately 700 SmartLids to about 80 accounts, with around 30 being new engagements [9][10] - Interventional glaucoma revenue growth was supported by a 2% increase in ordering accounts year-over-year, with utilization remaining healthy [14] Market Data and Key Metrics Changes - The interventional glaucoma market is expected to grow in the low to mid-single digits, while the interventional dry eye market is anticipated to grow significantly due to new reimbursement opportunities [25][26] - The current MIGS market is estimated to be 90% combo cataract and 10% standalone, with expectations for a shift towards standalone procedures [36] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A focus on interventional solutions is expected to create multiple durable growth drivers across glaucoma and dry eye treatments [7] - Investments in commercial infrastructure and market access are planned to support growth in both interventional dry eye and interventional glaucoma segments [22][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven without raising additional equity capital, emphasizing operational discipline [17] - The company is optimistic about the growth potential in both segments, particularly with the recent reimbursement milestones for interventional dry eye [22] - Management highlighted the importance of educating eye care providers on the benefits of earlier intervention with minimally invasive solutions for glaucoma [33] Other Important Information - The company ended Q4 2025 with $92 million in cash and cash equivalents, down from $120.4 million at the end of 2024 [19] - The company initiated revenue guidance for 2026 of $82 million to $88 million, reflecting growth of 6% to 14% compared to 2025 [20] Q&A Session Summary Question: Guidance assumptions for interventional glaucoma and interventional dry eye - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its reimbursement journey [25][26] Question: Standalone glaucoma market evolution and obstacles - Management noted that activating the standalone market requires education and a structured workflow similar to cataract surgery, with ongoing investments to facilitate this transition [33][36] Question: Operating expenses and investment balance - Management confirmed that investments in commercial infrastructure will focus on both interventional dry eye and glaucoma, while maintaining financial discipline [42][44] Question: TearCare peak sales potential - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time, emphasizing the need for market access [52][54] Question: First quarter outlook for interventional glaucoma - Management cited weather-related disruptions as a factor impacting the first quarter outlook, but did not foresee other significant headwinds [59]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $20.4 million, a 7% increase year-over-year [17] - Interventional glaucoma revenue was $19.7 million, up 5% year-over-year, while interventional dry eye revenue was $0.7 million, up from $0.3 million [17] - Gross margin was 87%, consistent with the prior year, with interventional glaucoma gross margin at 88% and interventional dry eye gross margin improved to 68% from 51% [18] - Total operating expenses decreased by 25% to $21.5 million compared to $28.5 million in the prior year [18] - Net loss was $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share in the previous year [19] - Cash and cash equivalents at the end of the quarter were $92 million, down from $120.4 million at the end of 2024 [19] Business Line Data and Key Metrics Changes - Interventional dry eye revenue in Q4 was $0.7 million, driven by the sale of approximately 700 Smart Lids to about 80 accounts, with 30 being new engagements [9][10] - Interventional glaucoma revenue was $19.7 million, with ordering accounts increasing by 2% year-over-year [13] - Utilization in interventional glaucoma remained healthy, down slightly after a strong Q3 [13] Market Data and Key Metrics Changes - The interventional dry eye market is expected to grow significantly, with a focus on expanding market access and engaging new eye care providers [11][12] - The interventional glaucoma market is projected to grow in the low to mid-single digits, with a focus on expanding the combo cataract segment and standalone market opportunities [25][27] Company Strategy and Development Direction - The company aims to return to double-digit growth while maintaining operational rigor and financial discipline [5] - A shift in terminology from surgical glaucoma and dry eye to interventional glaucoma and interventional dry eye reflects a focus on earlier procedure-based interventions [6] - Investments are being made in commercial infrastructure to support growth in both interventional dry eye and interventional glaucoma segments [21][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity within the interventional markets for glaucoma and dry eye, emphasizing the importance of their proprietary technologies [5][6] - The company is focused on pioneering the reimbursed interventional dry eye treatment market and enhancing customer engagement [11][12] - Management expects revenue guidance for 2026 to be between $82 million and $88 million, reflecting growth of 6% to 14% compared to 2025 [19][20] Other Important Information - The company has established pricing for CPT code 0563T associated with the TearCare procedure, marking a significant milestone for the interventional dry eye business model [9] - The company is actively engaging with additional MACs and commercial payers to accelerate adoption and expand access for patients [12][63] Q&A Session Summary Question: Can you provide color on low-end versus high-end assumptions for guidance? - Management indicated a stable market for interventional glaucoma and emphasized prudent guidance for interventional dry eye, which is still early in its market access journey [25][26] Question: What are the assumptions for underlying market growth in interventional glaucoma? - Management estimates low to mid-single digit market growth for interventional glaucoma [27] Question: How do you see the standalone glaucoma market evolving? - Management highlighted the importance of educating eye care providers on earlier interventions and activating the standalone market through targeted investments [34][36] Question: What is the revenue opportunity for dry eye in the two MACs? - Management noted a significant opportunity with 10.4 million covered lives and approximately 700,000 patients with moderate to severe MGD in those markets [46] Question: Can you discuss the peak sales potential of TearCare? - Management acknowledged the large market opportunity for TearCare but refrained from quantifying peak sales potential at this time [51][54] Question: What is the expectation for reimbursement with new goniotomy codes? - Management is aware of the potential impact of new goniotomy codes and expects some pressure on utilization but believes it could also create a tailwind for their OMNI technology [66]

🎉 The Omni Network (OMNI) token rebranding to Nomina (NOM) has been completed for https://t.co/vCNztATkNg users✅ $OMNI has been reissued as $NOM to holders in a 1:75 ratio✅ Trade, deposit and withdraw $NOM in the App and Exchange@NominaCrypto.com (@cryptocom):🚨 https://t.co/vCNztATkNg is supporting the Omni Network ($OMNI) token rebranding to Nomina ($NOM) 🚨✅ Trading, deposits, and withdrawals of OMNI will remain available in the App and on the Exchange until September 29, after which they will be permanent ...

ℹ️ A separate announcement will be made when the token migration is complete and when NOM trading, deposits, and withdrawals are enabled💡 The 1:75 reissue of $OMNI to $NOM is expected to take place at a later date. No action is required from users.Full details 👉 https://t.co/C1zizl9n0z ...

Network Upgrade & Token Conversion - Nomina 完成网络升级，将 OMNI 转换为 NOM [1] - Token 转换发生在交易所上市之前 [1]

Summary of Sight Sciences FY Conference Call (September 10, 2025) Company Overview - **Company**: Sight Sciences (NasdaqGS:SGHT) - **Industry**: Interventional Glaucoma and Dry Eye Treatment Key Points on the MIGS Market - **Market Growth**: The MIGS (Minimally Invasive Glaucoma Surgery) market is expected to return to growth in 2026 after facing headwinds due to LCD (Local Coverage Determinations) and payment changes in 2025 [3][4] - **Clinical Need**: Glaucoma is the leading cause of irreversible blindness globally, necessitating more interventional options for patients [3][5] - **Patient Visits**: There is a continuous increase in patient visits, indicating a growing demand for glaucoma treatments [3][4] - **Commercial Strategy**: The company aims to position itself strongly to capture growth when the MIGS market rebounds, emphasizing the importance of innovation and effective commercial execution [4][10] Insights on Glaucoma Treatment - **Interventional Approaches**: The future of glaucoma treatment is expected to be more interventional, with a focus on sustained release interventions and early use of SLT (Selective Laser Trabeculoplasty) [7][9] - **Patient Compliance**: The company recognizes the challenges of patient compliance with traditional treatments like eye drops, advocating for more effective interventional methods [6][9] Performance Metrics - **Q2 Performance**: Surgical glaucoma revenue was down mid-single digits, significantly better than the anticipated 15% decline due to MIGS restrictions. The company reported a 12% sequential increase in utilization [10][11] - **Surgeon Engagement**: The company has seen record numbers of ordering accounts, indicating strong engagement with its commercial team [10][11] Regulatory and Payer Dynamics - **Payer Scrutiny**: The rapid growth of the MIGS segment has led to increased scrutiny from payers, necessitating robust clinical evidence to support reimbursement [14][15] - **Clinical Evidence**: The company is focused on generating compelling clinical evidence to demonstrate the efficacy of its products, particularly the OMNI platform [16][50] OMNI Platform Innovations - **OMNI Edge**: The latest iteration of the OMNI platform, which enhances the volume of viscoelastic delivered during procedures, has received positive feedback from surgeons [17][18] - **Competitive Landscape**: The company believes it is ahead of competitors in technology and usability, which are critical factors for success in the market [20][21] Dry Eye Treatment Insights - **TearCare Development**: The company has developed TearCare to address the root causes of dry eye disease, focusing on meibomian gland dysfunction rather than tear insufficiency [25][28] - **Clinical Trials**: TearCare has completed two randomized controlled trials (RCTs) demonstrating its superiority over standard care, which is crucial for gaining reimbursement [29][50] - **Market Potential**: There are over 19 million diagnosed and an additional 19 million undiagnosed patients with dry eye disease in the U.S., indicating a significant market opportunity [43] Reimbursement Strategy - **Payer Engagement**: The company is actively engaging with payers to secure reimbursement for TearCare, leveraging strong clinical evidence and economic analyses [30][50] - **Future Goals**: The company aims for policy wins by 2025, with ongoing discussions and positive feedback from payers regarding the Sahara RCT [51][55] Conclusion - **Overall Outlook**: Sight Sciences is well-positioned in the interventional glaucoma and dry eye markets, with a strong focus on innovation, clinical evidence, and strategic payer engagement to drive future growth [4][50]

Portfolio Performance - The altcoin portfolio initially decreased by 75% and is currently down 50% [2] - One altcoin in the portfolio experienced a 250% increase in a single day [1] - The portfolio started with $110 thousand, and if it returns to the original buy-in levels, the valuation would be $235 thousand [3][4] Trading Strategy - The strategy involves actively trading and rebalancing the portfolio to scalp percentages and regain value quickly [2] - The approach includes selling assets that have performed well and reinvesting in those that haven't [3] - An example includes selling OMNI after a 250% pump following an Upbit listing [4][6] - Selling OMNI at $725 resulted in $55 thousand, which was reinvested into other assets [6][7] Risk Management - Holding OMNI would have resulted in a $3 thousand drawdown, while reinvesting the proceeds led to a smaller $600 loss [7][8] - Reinvesting $55 thousand from OMNI sales into other assets resulted in a current valuation of $4924 [7][8] - The reinvestment strategy aims to increase the potential to return to break-even [8] Specific Investments - $25 thousand was allocated to $W at $0085 [10] - $15 thousand was allocated to $RPL at $718 [10] - $15 thousand was allocated to $REZ at $00145 [10]

Community Roundup ✨We're celebrating one of our most dedicated Omnitrons: @ashishknows. A big thanks for putting $OMNI in the spotlight this week:📊 Top Voice with 24% mindshare⚡ Insights on gas refueling + what's coming nextWe love to see the community leading the charge. ...